Literature DB >> 35652624

Trimetazidine Blocks Lipid Oxidation-Should it be Repurposed for Prevention and Treatment of Diabetic Ketoacidosis?

David C Klonoff1, Nicole Y Xu2, Kevin T Nguyen2, David Kerr3, Chhavi Mehta4, Guillermo E Umpierrez5, George A Brooks6.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitor; ketoacidosis; metabolic modulator; repurpose; trimetazidine

Mesh：

Substances：

Year:  2022        PMID： 35652624      PMCID： PMC9445353          DOI： 10.1177/19322968221100196

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN： 1932-2968


× No keyword cloud information.
  31 in total

1.  Trimetazidine improves exercise performance in patients with peripheral arterial disease.

Authors:  Cristiana Vitale; Giuseppe Marazzi; Francesco Pelliccia; Maurizio Volterrani; Elena Cerquetani; Ilaria Spoletini; Giuseppe Mercuro; Stefano Bonassi; Valentina Dall'Armi; Massimo Fini; Giuseppe M C Rosano
Journal:  Pharmacol Res       Date:  2011-01-08       Impact factor: 7.658

Review 2.  Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.

Authors:  Hongyu Qiu; Aleksandra Novikov; Volker Vallon
Journal:  Diabetes Metab Res Rev       Date:  2017-02-23       Impact factor: 4.876

3.  Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments.

Authors:  E W Gertz; J A Wisneski; W C Stanley; R A Neese
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

4.  Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial.

Authors:  Selvarajan Sandhiya; Steven Aibor Dkhar; Ajith Ananthakrishna Pillai; Melvin George; Balachander Jayaraman; Adithan Chandrasekaran
Journal:  J Clin Diagn Res       Date:  2015-01-01

5.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

Authors:  G Fragasso; P M Piatti Md; L Monti; A Palloshi; E Setola; P Puccetti; G Calori; G D Lopaschuk; A Margonato
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

6.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

Authors:  Ele Ferrannini; Elza Muscelli; Silvia Frascerra; Simona Baldi; Andrea Mari; Tim Heise; Uli C Broedl; Hans-Juergen Woerle
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

7.  Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial.

Authors:  Letícia Weiss Ribeiro; Jorge P Ribeiro; Ricardo Stein; Cristiane Leitão; Carísi Anne Polanczyk
Journal:  Am Heart J       Date:  2007-07       Impact factor: 4.749

Review 8.  The Science and Translation of Lactate Shuttle Theory.

Authors:  George A Brooks
Journal:  Cell Metab       Date:  2018-04-03       Impact factor: 27.287

9.  Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.

Authors:  John R Ussher; Wendy Keung; Natasha Fillmore; Timothy R Koves; Jun Mori; Liyan Zhang; David G Lopaschuk; Olga R Ilkayeva; Cory S Wagg; Jagdip S Jaswal; Deborah M Muoio; Gary D Lopaschuk
Journal:  J Pharmacol Exp Ther       Date:  2014-04-03       Impact factor: 4.030

10.  Trimetazidine-Induced Parkinsonism: A Systematic Review.

Authors:  Anna Marielle B Dy; Lorenzo Luis G Limjoco; Roland Dominic G Jamora
Journal:  Front Neurol       Date:  2020-02-25       Impact factor: 4.003
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.